JP2022506829A5 - - Google Patents

Info

Publication number
JP2022506829A5
JP2022506829A5 JP2021524438A JP2021524438A JP2022506829A5 JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5 JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5
Authority
JP
Japan
Prior art keywords
cancer
breast cancer
eribulin
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061010 external-priority patent/WO2020097625A1/en
Publication of JP2022506829A publication Critical patent/JP2022506829A/ja
Publication of JP2022506829A5 publication Critical patent/JP2022506829A5/ja
Pending legal-status Critical Current

Links

JP2021524438A 2018-11-09 2019-11-12 エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン Pending JP2022506829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758388P 2018-11-09 2018-11-09
US62/758,388 2018-11-09
PCT/US2019/061010 WO2020097625A1 (en) 2018-11-09 2019-11-12 Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations

Publications (2)

Publication Number Publication Date
JP2022506829A JP2022506829A (ja) 2022-01-17
JP2022506829A5 true JP2022506829A5 (cg-RX-API-DMAC7.html) 2022-11-21

Family

ID=70612537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524438A Pending JP2022506829A (ja) 2018-11-09 2019-11-12 エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン

Country Status (5)

Country Link
US (1) US20210267986A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877422A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022506829A (cg-RX-API-DMAC7.html)
CN (1) CN113271977A (cg-RX-API-DMAC7.html)
WO (1) WO2020097625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
WO2022087018A1 (en) * 2020-10-19 2022-04-28 G1 Therapeutics, Inc. Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102186969B1 (ko) * 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
AU2013353745A1 (en) * 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 化学療法の間の正常細胞の一時的な保護
RU2016136504A (ru) * 2014-03-03 2018-04-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ
WO2015161283A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2015183961A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US20160166536A1 (en) * 2014-12-12 2016-06-16 Northwestern University Combination therapy for the treatment of cancer
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
IL317919A (en) * 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
JP7229162B2 (ja) * 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
EP3621633A2 (en) * 2017-05-11 2020-03-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER

Similar Documents

Publication Publication Date Title
JP2022031403A5 (cg-RX-API-DMAC7.html)
ES2561495T3 (es) Régimen de tratamiento que utiliza neratinib contra cáncer de mama
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
CA3146346A1 (en) 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
BR112020024062A2 (pt) métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
BR112020010435A2 (pt) uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia
JP2019529581A5 (cg-RX-API-DMAC7.html)
CN106573042A (zh) 治疗多发性骨髓瘤的药物组合
JP2017526695A5 (cg-RX-API-DMAC7.html)
TW202120096A (zh) 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌
CN119997942A (zh) 用于治疗癌症的化合物
JP2015517523A5 (cg-RX-API-DMAC7.html)
CN109069469A (zh) 治疗癌症的方法
JP2019526632A5 (cg-RX-API-DMAC7.html)
CN111184863A (zh) 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
JP2022506829A (ja) エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン
ES2841981T3 (es) Antihistamínico para su uso en el tratamiento del cáncer de mama
JP2013531073A5 (cg-RX-API-DMAC7.html)
JP5858989B2 (ja) 組合せ
JP2020521786A5 (cg-RX-API-DMAC7.html)
Chalasani Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations
WO2019017497A1 (en) USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
JP2020517739A (ja) リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体2陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ
JP2021138693A (ja) がんを処置するための方法
JP2017502989A5 (cg-RX-API-DMAC7.html)